Biotron

Biotron Limited (Biotron) is a clinical-stage, publicly listed Australian biotechnology company headquartered in Sydney, Australia. The company is developing and commercializing a novel small molecule approach with the potential to treat many serious viral diseases. The technology targets viroporin proteins, which are key to the pathogenicity of various viruses, including hepatitis C, HIV-1, dengue, Zika virus, influenza, and respiratory syncytial virus (RSV).